Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Boston Scientific BSX

Boston Scientific scores good on business quality (7.0 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$42.73Oct 9, 2026
Business qualityGood
Next earningsOct 28, 2026, before the open
Insiders, 90 daysBuying

Why it matters

  1. What Boston Scientific does

    Boston Scientific manufactures medical devices used in interventional cardiology, rhythm management, and endoscopy. Hospitals and physicians pay for catheters, stents, and imaging tools to treat complex cardiovascular and gastrointestinal diseases.

  2. What it does best

    Boston Scientific delivers top-decile revenue growth of 19.9%, outpacing peers like Abbott with 5.7% growth. This scale is driven by high switching costs in hospital cath labs, where physicians stick to trusted cardiovascular devices.

  3. The main risk

    Regulatory and market volatility poses ongoing threats, evidenced by recent stock dips despite broader market gains. Any delay in device approvals or hospital capital spending cuts directly impacts product adoption.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin stands at 20.9% with a 17.5% net margin, showing stable profitability. The business scales efficiently as top-line revenue expands.

MoatFair

Switching costs lock in hospital buyers and physicians who rely on specialized medical devices. Gross margin sits at 69.5%, supporting a solid medical technology moat.

GrowthFast

Revenue growth hit 19.9%, ranking in the 88th percentile of its sector. This top-line expansion accelerates cleanly over historical annual figures.

Financial healthStrong

Debt-to-equity sits at 0.5 with interest coverage at 12.1x, meaning debt costs are manageable. Free cash flow reached $3.6B, showing strong cash conversion and getting stronger.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

4 insiders bought $9.5M on the open market.

Our sealed record on BSX

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is BSX a good business?

Boston Scientific scores good on the Cluenex quality check (7.0 of 10), measured against its own industry. Profitability is fair, moat fair, growth fast and financial health strong.

Are insiders buying BSX?

In the last 90 days of SEC Form 4 filings: 4 insiders bought $9.5M on the open market.

When does BSX report earnings?

Oct 28, 2026, before the open.

For members

See BSX today

  • Today's verdict on BSX, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Boston Scientific (BSX)”, https://cluenex.com/stocks/bsx/, data as of Oct 10, 2026.